IN8bio Phase 1 INB-200 data shows 100% of GBM patients exceed historical median PFS

IN8BIO, INC.

100% (8/8) patients exceeded historical median PFS of 4-7 months; two patients from three-dose cohort remain progression-free at 23.5 and 19.4 months.
No treatment-related SAEs, DLTs, CRS, or ICANS reported; common TEAEs mild and linked to temozolomide.
Cohort 1 PFS ranged 7.4–11.9 months; Cohort 3 first patient had 7.1 months PFS with no brain progression.
Company on track to complete Phase 1 enrollment in 2023; further updates expected later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.